Publications by authors named "K L Foweraker"
Article Synopsis
- A study aimed to use deep learning on brain MRI scans to predict 8-month survival rates for glioblastoma patients after radiotherapy, involving data from 206 patients diagnosed across UK centers.
- The model's performance was tested against both imaging data (from MRI scans) and non-imaging data (like demographics) and showed high accuracy, particularly with imaging data outperforming non-imaging data.
- This deep learning model can help identify glioblastoma patients at higher risk of early mortality, potentially guiding them towards early second-line treatments or clinical trials.
Background: The mainstay of treatment for small cell lung cancer (SCLC) involves platinum doublet chemotherapy but the optimal duration, 4 vs. 6 cycles, is not known. Concurrent thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is recommended for fit individuals with limited stage.
View Article and Find Full Text PDFBackground: Radical chemoradiotherapy is the primary treatment for head and neck cancers in many hospitals. Tumour hypoxia causes radiotherapy resistance and is an indicator of poor prognosis for patients. Identifying hypoxia to select patients for intensified or hypoxia-modified treatment regimens is therefore of high clinical importance.
View Article and Find Full Text PDFAim: Continuous hyperfractionated accelerated radiotherapy (CHART) remains an option to treat non-small cell lung cancer (NSCLC; NICE, 2011). We have previously published treatment outcomes from 1998-2003 across five UK centres. Here we update the UK CHART experience, reporting outcomes and toxicities for patients treated between 2003 and 2009.
View Article and Find Full Text PDFArticle Synopsis
- Bevacizumab is a key treatment for schwannomas in Neurofibromatosis type 2 (NF2) patients in the UK, especially for those with rapidly growing tumors.
- Many patients experience tumor regrowth after stopping treatment, leading to prolonged use and associated risks.
- Common side effects include fatigue, hypertension, and proteinuria, with older age and specific dosing linked to higher hypertension rates; further research is needed to balance treatment effectiveness and reduce toxicity.